The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Vaishali Sanchorawala

Section of Hematology/Oncology

FGH 1007 820 Harrison Avenue

Boston

MA 02118

USA

[email]@bmc.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Section of Hematology/Oncology, FGH 1007 820 Harrison Avenue, Boston, MA 02118, USA. 2011
  • Stem Cell Transplantation Program of the Section of Hematology-Oncology, Boston University School of Medicine, Boston, MA 02118, USA. 2007
  • Section of Hematology/Oncology in the Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA. 2002 - 2007
  • Department of Medicine, Boston University Medical Center, Boston, USA. 2006 - 2007

References

  1. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Sanchorawala, V., Quillen, K., Sloan, J.M., Andrea, N.T., Seldin, D.C. Haematologica (2011) [Pubmed]
  2. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Sanchorawala, V., Skinner, M., Quillen, K., Finn, K.T., Doros, G., Seldin, D.C. Blood (2007) [Pubmed]
  3. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Sanchorawala, V., Wright, D.G., Quillen, K., Finn, K.T., Dember, L.M., Berk, J.L., Doros, G., Fisher, C., Skinner, M., Seldin, D.C. Bone Marrow Transplant. (2007) [Pubmed]
  4. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Sanchorawala, V., Seldin, D.C. Amyloid (2007) [Pubmed]
  5. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Sanchorawala, V., Wright, D.G., Rosenzweig, M., Finn, K.T., Fennessey, S., Zeldis, J.B., Skinner, M., Seldin, D.C. Blood (2007) [Pubmed]
  6. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Sanchorawala, V., Blanchard, E., Seldin, D.C., O'Hara, C., Skinner, M., Wright, D.G. Am. J. Hematol. (2006) [Pubmed]
  7. Light-chain (AL) amyloidosis: diagnosis and treatment. Sanchorawala, V. Clinical J. American Society Nephrology : Cjasn (2006) [Pubmed]
  8. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Sanchorawala, V., Seldin, D.C., Magnani, B., Skinner, M., Wright, D.G. Bone Marrow Transplant. (2005) [Pubmed]
  9. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Finn, K.T., Dember, L.M., Berk, J.L., Quillen, K., Anderson, J.J., Comenzo, R.L., Skinner, M. Bone Marrow Transplant. (2004) [Pubmed]
  10. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Berk, J.L., Dember, L.M., Finn, K.T., Skinner, M. Br. J. Haematol. (2002) [Pubmed]
 
WikiGenes - Universities